PT  - JOURNAL ARTICLE
AU  - Taghvaei, Amirhossein
AU  - Georgiou, Tryphon T.
AU  - Norton, Larry
AU  - Tannenbaum, Allen
TI  - Fractional SIR Epidemiological Models
AID  - 10.1101/2020.04.28.20083865
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.28.20083865
4099  - http://medrxiv.org/content/early/2020/05/08/2020.04.28.20083865.short
4100  - http://medrxiv.org/content/early/2020/05/08/2020.04.28.20083865.full
AB  - The purpose of this work is to make a case for epidemiological models with fractional exponent in the contribution of sub-populations to the transmission rate. More specifically, we question the standard assumption in the literature on epidemiological models, where the transmission rate dictating propagation of infections is taken to be proportional to the product between the infected and susceptible sub-populations; a model that relies on strong mixing between the two groups and widespread contact between members of the groups. We content, that contact between infected and susceptible individuals, especially during the early phases of an epidemic, takes place over a (possibly diffused) boundary between the respective sub-populations. As a result, the rate of transmission depends on the product of fractional powers instead. The intuition relies on the fact that infection grows in geographically concentrated cells, in contrast to the standard product model that relies on complete mixing of the susceptible to infected sub-populations. We validate the hypothesis of fractional exponents i) by numerical simulation for disease propagation in graphs imposing a local structure to allowed disease transmissions and ii) by fitting the model to a COVID-19 data set provided by John Hopkins University (JHUCSSE) for the period Jan-31-20 to Mar-24-20, for the countries of Italy, Germany, Iran, and France.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by AFOSR Grants FA9550-20-1-0029, FA9550-17-1-0435, NSF Grants 1807664, 1839441, National Institute of Aging Grant R01-AG048769, MSK Cancer Center Support Grant/Core Grant (P30 CA008748), and a grant from Breast Cancer Research Foundation BCRF-17-193.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used are publically available. https://github.com/CSSEGISandData/COVID-19